2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor

Related Products

PDF 2.76 MB

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-103088
    Palupiprant
    		Antagonist 99.96%
    Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities.
    Palupiprant
  • HY-101952S
    Prostaglandin E2-d4
    		Activator 99.90%
    Prostaglandin E2-d4 is the deuterium labeled Prostaglandin E2. Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
    Prostaglandin E2-d<sub>4</sub>
  • HY-16781
    Grapiprant
    		Antagonist 99.57%
    Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment[3] .
    Grapiprant
  • HY-16963
    GW627368
    		Antagonist 99.95%
    GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.
    GW627368
  • HY-B0191
    Bimatoprost
    		99.94%
    Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus.
    Bimatoprost
  • HY-128686
    KAG-308
    		Agonist 99.60%
    KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a Ki and an EC50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor.
    KAG-308
  • HY-15274
    L-798106
    		Antagonist 99.91%
    L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM, respectively.
    L-798106
  • HY-50175
    Laropiprant
    		Antagonist 99.34%
    Laropiprant is a potent and selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.
    Laropiprant
  • HY-108559
    L-161982
    		Inhibitor 99.33%
    L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.
    L-161982
  • HY-119163
    L-902688
    		Agonist 99.0%
    L-902688 is a potent, selective and orally active EP4 receptor agonist with a Ki of 0.38 nM and an EC50 of 0.6 nM. L-902688 shows >4,000-fold selective for EP4 over other EP and prostanoid receptors.
    L-902688
  • HY-108912
    RO1138452
    		Antagonist 99.26%
    RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pKi is 9.3±0.1; in a recombinant IP receptor system, pKi is 8.7±0.06.
    RO1138452
  • HY-113205
    15-keto-Prostaglandin E2
    		Activator ≥99.0%
    15-keto-Prostaglandin E2 (15-keto-PGE2) is an endogenous PGE2 metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to the Cys259 residue of STAT3. 15-keto-Prostaglandin E2 binds to and stabilizes EP2 and EP4 receptors. 15-keto-Prostaglandin E2 inhibits the growth and progression of breast cancer cells. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth. 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development and reduces the surface area of the glomerular filtration barrier.
    15-keto-Prostaglandin E2
  • HY-18971
    TG4-155
    		Antagonist 99.91%
    TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1. TG4-155 has an EP2 Schild KB of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor.
    TG4-155
  • HY-N0607
    Ginsenoside Ro
    		Inhibitor 99.81%
    Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
    Ginsenoside Ro
  • HY-10835
    DG-041
    		Antagonist 99.61%
    DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.
    DG-041
  • HY-B0584
    Travoprost
    		Agonist 99.99%
    Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.
    Travoprost
  • HY-16763
    Asapiprant
    		Antagonist 99.89%
    Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.
    Asapiprant
  • HY-17642
    Omidenepag
    		Agonist 99.86%
    Omidenepag (UR-7276), a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid EP2 receptor agonist, with an EC50 of 1.1 nM. Omidenepag shows binding affinities (IC50) 10 nM for h-EP2. Omidenepag is used in research on diseases related to intraocular pressure.
    Omidenepag
  • HY-101987
    BW 245C
    		Agonist 99.35%
    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to study stroke.
    BW 245C
  • HY-113756A
    Latanoprost acid
    		Agonist 98.77%
    Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes.
    Latanoprost acid
Cat. No. Product Name / Synonyms Application Reactivity
Prostaglandin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.